Xeraya Capital

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Imago BioSciences, Inc. is a clinical-stage biotechnology company based in Redwood City, California, founded in 2012. The company specializes in developing novel small molecule therapeutics aimed at treating hematologic diseases, including myelodysplastic syndromes, acute myelogenous leukemia, and other conditions associated with bone marrow failure. Central to its research is the enzyme lysine-specific demethylase 1 (LSD1), which is involved in the regulation of blood cell production. Imago BioSciences is focused on translating advanced scientific insights into transformative therapies that can alter the course of disease, thereby enhancing the quality and longevity of life for patients. Its lead product candidate, Bomedemstat, is an orally administered LSD1 inhibitor currently under evaluation for its potential to modify disease progression in patients with myeloproliferative neoplasms, a group of chronic bone marrow cancers.

InterVenn is a life science company focused on revolutionizing healthcare through the study of glycoproteomics, which involves glycosylated proteins that significantly influence protein function. By developing an innovative AI-powered platform, InterVenn decodes the complex glycoproteome, providing critical biological insights that were previously unattainable. This technology enables the identification, quantification, and classification of glycoproteomic signals in human blood and tissue, facilitating early detection and triaging of cancers, particularly ovarian cancer. InterVenn’s platform supports the creation of a diverse range of clinical applications, from disease screening to diagnostics, and has the potential to contribute to therapeutics. Founded by renowned experts, including Nobel Laureate Dr. Carolyn Bertozzi, InterVenn aims to advance personalized, predictive, and preventative healthcare solutions, enhancing patient outcomes and aiding pharmaceutical partners in their research and development efforts.

Congenica Ltd. is a biotechnology company that specializes in clinical data solutions for genetic diagnosis. Established in 2012 and headquartered in Hinxton, United Kingdom, it offers the Sapientia platform, a clinical genomic analytics tool that integrates human DNA sequences with deep clinical phenotyping. This platform enables clinicians and researchers to interpret genetic diseases and provides actionable insights for diagnosis, prognosis, and research. Additionally, Sapientia supports personalized medicine by facilitating the creation of disease registries, identifying patient populations for clinical studies, and aiding in the discovery of novel drug targets and biomarkers. Congenica's focus is on improving clinical outcomes through advanced genomic analysis.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

GreenLight Biosciences, Inc. is a biotechnology company headquartered in Medford, Massachusetts, with an additional location in North Carolina. Founded in 2008, the company specializes in developing RNA-based solutions for agricultural and pharmaceutical purposes. It offers a proprietary technology platform that enables the efficient and cost-effective production of high-quality RNA, facilitating advancements in vaccine development, pandemic response, crop management, and the protection of pollinators. GreenLight develops mRNA-based vaccine candidates, including those aimed at preventing SARS-CoV-2 infections, and engages in collaborative efforts with industry leaders to further enhance its offerings. Through its innovative approach, GreenLight aims to contribute significantly to sustainable global development and food security.

Aria CV, Inc. is a medical device company based in St. Paul, Minnesota, specializing in treatments for pulmonary arterial hypertension (PAH). Founded in 2010 by Drs. John Scandurra and Karl Vollmers, the company has developed an innovative implantable cardiovascular device aimed at reducing the workload on the right side of the heart. This device holds the potential to enhance both the survival and quality of life for patients suffering from pulmonary hypertension. Aria CV has secured an exclusive license for certain patents from the University of Minnesota, reflecting its commitment to advancing medical technology in this critical area of healthcare.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Rapid Micro Biosystems, Inc. is a life sciences technology company specializing in the detection of microbial contamination in the pharmaceutical, biotechnology, and personal care product manufacturing sectors. Founded in 2006 and based in Lowell, Massachusetts, with an additional office in Germany, the company offers the Growth Direct System, an automated platform designed to modernize and streamline microbial quality control testing workflows. This system includes automated imaging and analysis of proprietary consumables, providing a non-destructive method for microbial enumeration. In addition to its core products, Rapid Micro Biosystems offers services such as on-site installation, regulatory compliance assistance, validation, technical support, and training. Its solutions are applicable in environmental monitoring, water testing, and bioburden testing, facilitating the efficient manufacturing and safe release of healthcare products like biologics and vaccines.

Liquidia Technologies is a late-stage clinical biopharmaceutical company based in the United States, dedicated to developing and commercializing innovative therapeutics. Utilizing its proprietary PRINT technology, a particle engineering platform, Liquidia produces uniform drug particles aimed at enhancing the safety and efficacy of various therapies. The company is advancing two key product candidates: LIQ861, intended for the treatment of pulmonary arterial hypertension, and LIQ865, designed for managing local post-operative pain. Additionally, Liquidia collaborates with leading pharmaceutical firms to leverage its PRINT technology across multiple therapeutic areas, molecule types, and administration routes, addressing unmet patient needs, particularly in the realm of pulmonary hypertension.

Consumer Physics Inc. is a Tel Aviv-based company that develops and distributes molecular sensors, primarily marketed under the SCiO brand. Founded in 2011, the company aims to empower consumers and businesses to analyze the composition of materials in real-time using its compact near-infrared (NIR) spectrometer. The SCiO device integrates with smartphone applications and connects to a cloud-based database that stores material fingerprints. This technology is particularly beneficial for industries such as food and agriculture, as it enables users to make informed decisions, reduce waste, and enhance profitability. Consumer Physics also provides a platform for businesses and third-party developers to create their own molecular sensing models and mobile applications, supported by tools like the SCiO Lab development platform and Mobile SDK.

Founded in 2009 by Yale scientists and a chemical industry veteran, P2 Science is a venture-backed company specializing in renewable specialty chemicals. It converts renewable feedstocks like vegetable oils into high-value products such as flavor, fragrance, and cosmetics ingredients, serving diverse markets including food, personal care, and industrial cleaning.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

Iconic Therapeutics, Inc. is a biopharmaceutical company based in South San Francisco, California, that focuses on developing innovative therapeutics targeting retinal diseases and cancer through the biology of tissue factor. The company has an exclusive license for a novel recombinant protein known as hI-con1, which functions as an immunoconjugate that activates the immune system to eliminate pathological cells, such as those involved in wet age-related macular degeneration and certain cancers. hI-con1 binds to tissue factor, prompting natural killer cells to destroy aberrant neovascular blood vessels and potentially disrupting the feedback loop with vascular endothelial growth factor (VEGF), thus reducing its levels. Phase 1 studies of hI-con1 have shown promising results, demonstrating biological activity without dose-limiting toxicities. Iconic Therapeutics aims to translate scientific insights into effective treatments for serious diseases by addressing the underlying causes of inflammation and angiogenesis.

Acutus Medical, Inc. is an arrhythmia management company specializing in the development of medical technologies for the diagnosis and treatment of complex cardiac arrhythmias. Founded in 2011 and headquartered in Carlsbad, California, the company designs, manufactures, and markets a comprehensive range of tools for catheter-based ablation procedures. Its product portfolio includes advanced imaging and navigation systems, such as the AcQMap console and workstation, alongside various diagnostic and therapeutic devices like mapping and ablation catheters. Acutus Medical's innovative platform enables electrophysiologists to visualize the heart's activation patterns, facilitating more effective treatment strategies. The company collaborates with medical scientists and engineers in both the U.S. and Europe to enhance its offerings. Acutus Medical markets its products worldwide, primarily targeting hospitals and electrophysiologists engaged in arrhythmia care.

Boston Neurosciences is a medical device company specializing in neurodiagnostics. Founded in 2013 and headquartered in Waltham, Massachusetts, with additional offices in Kaunas, Lithuania, the company focuses on developing ultrasound-based devices for non-invasive measurement of intracranial pressure (ICP) and related neurological parameters. Their flagship product, BNS ICP 3, utilizes ultrasound Doppler technology to provide real-time, non-invasive ICP measurements. This technology has been clinically tested and validated in leading neuro centers across Europe and the United States, offering a safer and more efficient diagnostic method for conditions such as traumatic brain injury, concussion, hydrocephalus, stroke, and brain tumors.

ViewRay, Inc. is a medical technology company that specializes in designing, manufacturing, and marketing advanced radiation therapy systems for cancer treatment. Its flagship product, MRIdian, is a magnetic resonance image-guided radiation therapy system that simultaneously images and treats cancer patients. By integrating MRI technology with radiation delivery and proprietary software, MRIdian enhances the precision of radiation therapy. It can accurately locate and target soft-tissue tumors while minimizing exposure to surrounding healthy tissue. This capability allows clinicians to treat patients who might not have been suitable candidates for traditional radiation therapy, ultimately leading to improved safety and effectiveness in treatment outcomes. Headquartered in Oakwood, Ohio, ViewRay serves a diverse range of healthcare institutions, including university research hospitals, community hospitals, and freestanding cancer centers, and operates both domestically and internationally. The company was founded in 2004.

PrIME Biologics Pte Ltd. is a biotechnology company based in Singapore that specializes in the development and manufacturing of therapeutic plasma products. Founded in 2010 and formerly known as Singapharm Pte Ltd., the company focuses on producing therapeutic Albumin, IVIG, FVIII, FIX, and other plasma-based products, including hyperimmune therapies. PrIME Biologics employs an innovative manufacturing process called Preparative Isolation by Membrane Electrophoresis, which enhances the safety of its products by effectively removing viruses, bacteria, endotoxins, and prions. This cutting-edge approach positions the company to tap into the growing Asian plasma derivative market, valued at approximately US$1 billion.

Invendo Medical GmbH is a developer and manufacturer of sterile, single-use, robotically-assisted high-definition endoscopy products specifically designed for gastroenterology and gastrointestinal surgery. The company's flagship product, the invendoscopy E200 System, comprises a sterile colonoscope, a handheld control unit, and a supply and processing unit, providing a comprehensive solution for healthcare providers in the United States and Europe. Founded in 2001 and headquartered in Weinheim, Germany, Invendo Medical aims to enhance patient compliance and increase the number of gastroenterological procedures through innovative design and technology. The company, previously known as STM Medizintechnik GmbH, rebranded in 2006 and operates as a subsidiary of Ambu A/S. Invendo Medical focuses on developing highly flexible and easy-to-use endoscopy products, addressing the challenges associated with traditional gastrointestinal endoscopy methods.

Gevo specializes in producing renewable fuels and chemicals using sustainable resources. Its primary products include gasoline, jet fuel, diesel fuel, isobutanol, and renewable natural gas. The company aims to reduce greenhouse gas emissions by providing low-carbon alternatives to fossil fuels.